C12-15 ALKYL BENZOATE
化粧品における C12-15 ALKYL BENZOATE のグローバル配合基準と処方特性とは?
C12-15 ALKYL BENZOATE(CAS番号: 68411-27-8)は、化粧品処方において主に抗菌剤, 皮膚コンディショニング剤, エモリエント剤として配合される原料です。日本厚労省/JCIA(規制なし)、韓国MFDS(規制なし)、欧州CosIng(規制なし)など6大法域の法定基準下で管理され、通常 2–20%(適正安定域 pH 4–8)で処方されます。
7大トラック 国別・用途別 公式全成分表示名称マトリクス
各国公的告示原典のみ収録 · 機械翻訳・任意音訳ゼロ| 法域・規制トラック | 公式全成分表示名称 | ワンクリックコピー |
|---|---|---|
| ① 韓国 (MFDS 化粧品標準名称) | C12-15 ALKYL BENZOATE (KR MFDS Registered) | |
| ② 韓国旧名称履歴 (301 リダイレクト) | — | — |
| ③ 欧州連合 (EU CosIng EC 1223/2009) | C12-15 ALKYL BENZOATE | |
| ④ 米国一般化粧品 (US PCPC / MoCRA INCI) | C12-15 ALKYL BENZOATE | |
| ⑤ 米国 FDA OTC モノグラフ有効成分名 | — (米国 OTC 対象外 / 一般化粧品原料) | — |
| ⑥ 中国 (NMPA IECIC 標準中国語名称) | C12-15 醇苯甲酸酯 | |
| ⑦ 日本化粧品表示名称 / 医薬部外品外原規名称 (JCIA / MHLW) | C12-15 ALKYL BENZOATE (標準INCI参照 · 任意カタカナ音訳排除) |
Layer 1 — 6大法域 法定配合上限および規制ステータス
| 法域 | 規制ステータス | 配合上限 | 制限条件および一次法源出典 |
|---|---|---|---|
| 韓国 (MFDS) | 規制なし | GMP | 公的化粧品原料目録収載 (GMP基準内使用) |
| 欧州 (EU) | 規制なし | GMP | 公的化粧品原料目録収載 (GMP基準内使用) |
| 米国 (FDA) | 規制なし | GMP | 公的化粧品原料目録収載 (GMP基準内使用) |
| 中国 (NMPA) | 配合可能 | GMP | IECIC Entry #134 |
| 日本 (MHLW) | 規制なし | GMP | 公的化粧品原料目録収載 (GMP基準内使用) |
| ASEAN (ACD) | 規制なし | GMP | 公的化粧品原料目録収載 (GMP基準内使用) |
Layer 2 — 毒性・安全性評価上限 (US CIR / EU SCCS / CN IECIC)
「欧州 SCCS 安全性評価上限」は消費者安全科学委員会が安全域 (MoS≥100) と判定した毒性学的上限であり、「米国 CIR 市販製品最大報告濃度」および「中国 IECIC 最高歴史使用量」は市販製品における最大実績濃度です。
| 安全性評価基準 | 適用範囲・用途 | 安全濃度範囲 | 判定結果および文献参照 |
|---|---|---|---|
| 米国 CIR 市販製品最大報告濃度 | total | 0.0008~59% | 安全判定 (MoS≥100)116_draft_alkyl.pdf () |
| 米国 CIR 市販製品最大報告濃度 | leave_on | 0.0008~59% | 安全判定 (MoS≥100)116_draft_alkyl.pdf () |
| 米国 CIR 市販製品最大報告濃度 | rinse_off | 0.1~50% | 安全判定 (MoS≥100)116_draft_alkyl.pdf () |
| 米国 CIR 市販製品最大報告濃度 | eye | 0.0008~11% | 安全判定 (MoS≥100)116_draft_alkyl.pdf () |
| 米国 CIR 市販製品最大報告濃度 | ingestion | 3~16% | 安全判定 (MoS≥100)116_draft_alkyl.pdf () |
| 米国 CIR 市販製品最大報告濃度 | spray | 0.3~12% | 安全判定 (MoS≥100)116_draft_alkyl.pdf () |
| 米国 CIR 市販製品最大報告濃度 | dermal | 0.0008~59% | 安全判定 (MoS≥100)116_draft_alkyl.pdf () |
| 米国 CIR 市販製品最大報告濃度 | deodorant | 0.004~12% | 安全判定 (MoS≥100)116_draft_alkyl.pdf () |
| 米国 CIR 市販製品最大報告濃度 | hair | 0.3~35% | 安全判定 (MoS≥100)116_draft_alkyl.pdf () |
| 米国 CIR 市販製品最大報告濃度 | hair_dye | 0.5~2% | 安全判定 (MoS≥100)116_draft_alkyl.pdf () |
| 米国 CIR 市販製品最大報告濃度 | nail | 0.008~10% | 安全判定 (MoS≥100)116_draft_alkyl.pdf () |
| 米国 CIR 市販製品最大報告濃度 | mucous | 0.01~0.04% | 安全判定 (MoS≥100)116_draft_alkyl.pdf () |
| 米国 CIR 市販製品最大報告濃度 | baby | 10~10% | 安全判定 (MoS≥100)116_draft_alkyl.pdf () |
| 米国 CIR 市販製品最大報告濃度 | bath | 0.008~10% | 安全判定 (MoS≥100)117_tent_benzoa.pdf () |
| 中国 IECIC 最高歴史使用量 | leave_on | ≤ 30% | 安全判定 (MoS≥100)NMPA IECIC (2025) Entry 00971 (2025) |
| 中国 IECIC 最高歴史使用量 | rinse_off | ≤ 15% | 安全判定 (MoS≥100)NMPA IECIC (2025) Entry 00971 (2025) |
Layer 3 Formulation Concentration Box-Plot vs. Statutory Limit
Layer 3 — 剤形別通常配合濃度 (四分位数 n≥5) & 物理化学・相溶性ガイド
| 剤形グループ | Min – Q1 – Median – Q3 – Max (%) | 処方役割・作用機序 | Source ID |
|---|---|---|---|
| 剤形群 A — 水성化粧水・美容液・アンプル | 2% · 3% · 4% · 12.5% · 20% | Aqueous serum, toner & hydrogel matrix formulation component | Global Starter Formulation Library Statistical Distribution (n=8, ELEMENTIS 5 · SEPPIC 3) |
| 剤形群 D — 日焼け止め (UV)・メイクアップ・ファンデーション | 3% · 4.125% · 8% · 10.175% · 20% | Sun care & color cosmetics dispersion / sensory modifier | Global Starter Formulation Library Statistical Distribution (n=8, ELEMENTIS 3 · GRANT 3 · EVONIK 1 · SEPPIC 1) |
Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery
Under passive topical application, molecules diffuse tortuously through intercellular lipids. Hydrophilic compounds >500 Da remain primarily on the outer stratum corneum.
pH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior
Outside pH 4–8, risk of hydrolysis, viscosity loss, or ionic dissociation increases.
Thermally stable up to 50°C during standard emulsification.
Cellular & Molecular Target Mechanism Flow
Interactive Synergy Pairings (Solid) & Incompatibility Warnings (Dashed)
Click any green synergy node to jump directly to its monograph, or click a red dashed node to inspect the chemical incompatibility mechanism.
商品名は研究者がグレードを識別するための参考表記であり、各商標権は原メーカーに帰属します。
学術・毒性・処方統合モノグラフ
Tier 1 Synthesis本原料に紐づく NIH PubMed 査読付き論文アブストラクトおよび公的毒性評価報告書のみに基づいて作成された学術要約です。
関連査読付き学術論文 (NIH PubMed) (4)
Dermal absorption and metabolism of 14C-C12 alkyl benzoate in Finsolv TN in human skin in vitro [PMID: 40504031 · 2025]
C12 alkyl benzoate is present in the commercial emollient cosmetic ingredient C12-15 alkyl benzoate (Finsolv TN). Finsolv TN is a mixture of linear and branched esters of benzoic acid and aliphatic alcohols where linear C12 alkyl benzoate is a representative homolog with the shortest alkyl C-chain and lowest molecular weight. A preliminary non-GLP in vitro skin penetration study which monitored dermal bioavailability of all C12-15 alkyl benzoate constituents using GC-MS was carried out which demonstrated C12 alkyl benzoate could be considered a worst-case representative constituent to determine dermal absorption of the overall substance. Subsequently, [14C]-C12 alkyl benzoate was mixed into Finsolv TN, and applied, neat (10 µl/cm2), to dermatomed human skin mounted in a flow-through diffusion cell system. Receptor fluid was collected up to 24 h postdose and the skin was decontaminated at 8 h postdose. The absorbed dose, dermal delivery, potentially absorbable dose and dermally absorbed value of [14C]-C12 alkyl benzoate were 0.41%, 0.97%, 2.20%, and 2.97%, respectively. Metabolism during absorption was assessed in skin from the same donors, with no C12 alkyl benzoate detected in the receptor fluid, although the primary metabolite, [14C]-benzoic acid (>93%), was detected. A phenyl acetate esterase assay confirmed the presence of esterase activity in the donor skins used. Therefore, this study confirmed that dermal exposure of C12-15 alkyl benzoate (Finsolv TN) results in an absorbed dose of 2.97% completely metabolized to benzoic acid and aliphatic alcohol(s) in human skin. These findings indicate that a more in-depth investigation and assessment of toxicokinetic behavior (specifically for occupational exposures via the skin) provide opportunities to develop exposure-led strategies to avoid unnecessary animal testing allowing registrants to fulfill obligations to adhere to the "last resort" principle under REACH.
Effect of emollients on UV filter absorbance and sunscreen efficiency [PMID: 32065958 · 2020]
The idea of increasing the performance of sunscreens without adding more UV-filters is very attractive. Early studies reported an influence of solvents on the absorbing properties of UV-absorbers which was shown to be connected to the solvent polarity. However, the polarity differed a lot between tested solvents and most were unsuitable UV-filter solubilizers. The aim of the present study was to focus exclusively on emollients pertinent for sunscreens and investigate their impact on the performance of UV-filter combinations. The UV absorbance of Bis-ethylhexyloxyphenol Methoxyphenyl Triazine, Ethylhexyl Triazone, Diethylamino Hydroxybenzoyl Hexyl Benzoate, and Ethylhexyl Methoxycinnamate was measured in suncare relevant emollients comprising C12-15 Alkyl Benzoate, Dibutyl Adipate, Caprylic/Capric Triglyceride, Coco-caprylate, Isopropyl Myristate, Dicaprylyl Carbonate. The wavelength of maximum absorbance (λmax) and specific extinction at λmax (E1,1 (λmax) ) were assessed for each UV-filter - emollient system. The performance of market relevant UV-filter combinations based on the studied UV-filters was simulated for each emollient with a computational method using the absorbance values measured for each UV-filter - emollient system. The difference in polarity of emollients led to a 2-3 nm bathochromic shift and a variation of the E1,1 (λmax) ranging from 4 to 20% for tested UV-filters. The emollient type showed nearly no influence on the sun protection factor (SPF) of market relevant UV-filter combinations probably due to a different influence an emollient shows on the UVB filters resulting in cancelling of the corresponding effect. Conversely, for all UV-filter combinations the UVA protection decreased with a decrease in the emollient polarity. Whilst the SPF was not impacted by standardly used cosmetic oils, the results advocate to use polar emollients to optimize the UVA protection. This is of advantage since polar emollients better dissolve crystalline UV-filters. From tested emollients, Dibutyl Adipate performed the best for both SPF and PPD factors.
C12-15 alkyl benzoate: a new cosmetic allergen? [PMID: 25943945 · 2015]
Stability of benzoyl peroxide in aromatic ester-containing topical formulations [PMID: 18161634 · 2007]
The chemical stability of benzoyl peroxide (BPO) was studied in solutions and gels. The solutions (1% w/v) were prepared in single solvents (alcohol USP, isopropyl alcohol USP, ethyl benzoate, C12-15 alkyl benzoate, dimethyl isosorbide, propylene carbonate, and acetone) and in binary and tertiary combinations of these solvents, with and without the addition of antioxidant(s) (BHT, BHA, eugenol, tert-butyl hydroquinone, Tenox-2, vitamin E, and vitamin C). The solutions were stored at 37 degrees C for 5 weeks, and each week were analyzed for remaining BPO. Using first-order kinetics, the stability of BPO in solution was found to decrease in the order: ternary>binary>single solvent systems. Regardless of the number of solvents present, the highest stability of BPO (t1/2>7.5 weeks) was attained in the presence of ethyl benzoate and C12-15 alkyl benzoate. The stability of BPO in solution did not change significantly with the addition of most antioxidants. The solutions in which BPO remained most stable were one in alcohol USP-ethyl benzoate-C12-15 alkyl benzoate (60:20:20; t1/2=18.15 weeks) and another in alcohol USP-C12-15 alkyl benzoate-isopropanol plus 0.1% BHT (65:20:15; t1/2=12.44 weeks). In turn, these two solutions were converted to homogeneous gels by the addition of Cab-O-Sil. The chemical stability of BPO in these gels was evaluated at 37 degrees, 45 degrees, 50 degrees, and 55 degrees C for 5 weeks. Parallel experiments were conducted with two commercial BPO products, a 2.5% tinted gel and 5% vanishing lotion. BPO was less stable in commercial products (t1/2<or=13 weeks) than in the extemporaneously prepared gels (mean t1/2 approximately 23 weeks). The present results suggest that aromatic esters can enhance the chemical stability of BPO in solutions and gel formulations to a significant extent.
よくある質問 (FAQ)
- Q1. C12-15 ALKYL BENZOATE の各国公式全成分表示名称(7トラック)はどのように異なりますか?
- 日本化粧品工業連合会(JCIA)表示名称は 'C12-15 ALKYL BENZOATE (標準INCI準拠)'、米国PCPC・欧州CosIng INCIは 'C12-15 ALKYL BENZOATE'、中国NMPA IECIC標準中国語名は 'C12-15 醇苯甲酸酯' です。
- Q2. C12-15 ALKYL BENZOATE のグローバル6大法域における法定配合基準 (Layer 1) は?
- 6大法域規制ステータス — 日本(JP): none、韓国(KR): none、欧州(EU): none、米国(US): none、中国(CN): allowed、ASEAN: none。
- Q3. 処方設計における C12-15 ALKYL BENZOATE の通常配合濃度 (Layer 3) と適正 pH は?
- 主要剤形 (aqueous_serum) において通常 2〜20%(中央値 4%)で配合され、適正pH範囲は 4〜8 です。
- Q4. C12-15 ALKYL BENZOATE の配合禁忌 (Incompatibilities) と推奨シナジー成分は?
- 推奨シナジーペアは GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL、配合上の注意点は Verify phase compatibility under extreme pH or high electrolyte loads です。